A venture capital firm headquartered in USA currently manages 3 funds, and also has an advisory business that is solely dedicated for companies trying to enter the Asian market. The firm has a focus on early-stage investments (pre-Series A to Series B) and has portfolio companies spread over the USA. The firm’s initial investment size varies, but typically falls under the $250K – 2.5M range and is dedicated to follow-on financings of existing portfolio companies. The firm invests only in USA and Canada.
Within life sciences/healthcare, the firm is most interested in medical devices and smart manufacturing in life sciences, and is much more selective when it comes to biotech or therapeutics investments. Most importantly, the firm is focused on assessing the company’s patent status and the degree of novelty. While the firm is agnostic to stage of development, ideally the companies should have a working prototype and significant key data that validates the high potential of their technology. In terms of different types of technologies or diseases areas/indications, the firm is opportunistic.
The firm has no specific management team requirements, but considers patent strategy key in reviewing potential investments. Companies should have key patents issued or a clear strategy on improving their IP portfolio. The firm has great expertise in helping USA/Canada-based companies enter Asian markets (i.e. greater China) and extend their IP coverage. The firm can act as either lead or co-investor and will seek a board seat if they come in as a lead investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply